Who is eligible for clinical trial NCT06744647?

Participants must meet protocol criteria for Antibody-Mediated Rejection. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06744647 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-10

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation (NCT06744647)

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Alexion Pharmaceuticals, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.

Who can join: Review the eligibility criteria below.

Location: Research Site — Birmingham, Alabama

Age range: 18 Years to 75 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (51 Sites)

Showing the first 25 of 51 sites.

Research Site — Birmingham, Alabama
Research Site — Scottsdale, Arizona
Research Site — Los Angeles, California
Research Site — Orange, California
Research Site — Tampa, Florida
Research Site — Atlanta, Georgia
Research Site — Kansas City, Kansas
Research Site — Ann Arbor, Michigan
Research Site — Detroit, Michigan
Research Site — Livingston, New Jersey
Research Site — New York, New York
Research Site — New York, New York
Research Site — New York, New York
Research Site — Durham, North Carolina
Research Site — Cincinnati, Ohio
Research Site — Philadelphia, Pennsylvania
Research Site — Dallas, Texas
Research Site — Houston, Texas
Research Site — Richmond, Virginia
Research Site — Seattle, Washington
Research Site — Milwaukee, Wisconsin
Research Site — Botucatu,
Research Site — Campinas,
Research Site — Porto Alegre,
Research Site — São Paulo,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Antibody-Mediated Rejection

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) — Los Angeles, California
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) — Birmingham, Alabama
Biorepository and Registry for Plasma Exchange Patients — Iowa City, Iowa

Explore by condition: All Antibody-Mediated Rejection clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗